Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 Aug;147(2):238–244.

Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis.

T Wisniewski 1, A A Golabek 1, E Kida 1, K E Wisniewski 1, B Frangione 1
PMCID: PMC1869828  PMID: 7639323

Abstract

Several apolipoproteins are known to be closely associated with amyloid fibrillogenesis. Serum amyloid A, apolipoprotein (apo) AII and apo A1 are each deposited as biochemically distinct forms of amyloid. Late-onset Alzheimer's disease is linked to one isotype of apo E, apo E4. Apo E and apo E4 in particular have been shown to modulate amyloid fibril formation by amyloid-beta peptides in vitro. Furthermore, the carboxy terminus of apo E has been shown to be a constituent of plaque amyloid. We show immunohistochemically and electron microscopically the presence of apo A1 in senile plaques. The intact apo A1 can itself form amyloid-like fibrils in vitro that are Congo Red positive. We propose that some proteins when misfolded can propagate this misfolding to identical units, either autocatalytically or to other proteins that are induced to fold into the same abnormal conformation. This conformational mimicry may initiate and/or augment fibrillogenesis in Alzheimer's disease.

Full text

PDF
238

Images in this article

240Figure 1
on p.240
241Figure 3
on p.241
241Figure 2
on p.241

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Busciglio J., Gabuzda D. H., Matsudaira P., Yankner B. A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2092–2096. doi: 10.1073/pnas.90.5.2092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Calandra S., Tarugi P. Synthesis and secretion of apolipoprotein A-I. Biochem Soc Trans. 1993 May;21(2):493–499. doi: 10.1042/bst0210493. [DOI] [PubMed] [Google Scholar]
  3. Choi-Miura N. H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., Tomita M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 1992;83(3):260–264. doi: 10.1007/BF00296787. [DOI] [PubMed] [Google Scholar]
  4. Cohen F. E., Pan K. M., Huang Z., Baldwin M., Fletterick R. J., Prusiner S. B. Structural clues to prion replication. Science. 1994 Apr 22;264(5158):530–531. doi: 10.1126/science.7909169. [DOI] [PubMed] [Google Scholar]
  5. Gajdusek D. C. Nucleation of amyloidogenesis in infectious and noninfectious amyloidoses of brain. Ann N Y Acad Sci. 1994 Jun 6;724:173–190. doi: 10.1111/j.1749-6632.1994.tb38909.x. [DOI] [PubMed] [Google Scholar]
  6. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T., Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J. 1993 Jul 1;293(Pt 1):27–30. doi: 10.1042/bj2930027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ghiso J., Wisniewski T., Frangione B. Unifying features of systemic and cerebral amyloidosis. Mol Neurobiol. 1994 Feb;8(1):49–64. doi: 10.1007/BF02778007. [DOI] [PubMed] [Google Scholar]
  8. Glenner G. G., Wong C. W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984 Aug 16;122(3):1131–1135. doi: 10.1016/0006-291x(84)91209-9. [DOI] [PubMed] [Google Scholar]
  9. Golabek A., Marques M. A., Lalowski M., Wisniewski T. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett. 1995 May 19;191(1-2):79–82. doi: 10.1016/0304-3940(95)11565-7. [DOI] [PubMed] [Google Scholar]
  10. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992 Sep 24;359(6393):322–325. doi: 10.1038/359322a0. [DOI] [PubMed] [Google Scholar]
  11. Jenne D. E., Lowin B., Peitsch M. C., Böttcher A., Schmitz G., Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem. 1991 Jun 15;266(17):11030–11036. [PubMed] [Google Scholar]
  12. Johnson K. H., Sletten K., Hayden D. W., O'Brien T. D., Roertgen K. E., Westermark P. Pulmonary vascular amyloidosis in aged dogs. A new form of spontaneously occurring amyloidosis derived from apolipoprotein AI. Am J Pathol. 1992 Nov;141(5):1013–1019. [PMC free article] [PubMed] [Google Scholar]
  13. Kida E., Golabek A. A., Wisniewski T., Wisniewski K. E. Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. Neurosci Lett. 1994 Feb 14;167(1-2):73–76. doi: 10.1016/0304-3940(94)91030-8. [DOI] [PubMed] [Google Scholar]
  14. Koudinov A., Matsubara E., Frangione B., Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1164–1171. doi: 10.1006/bbrc.1994.2788. [DOI] [PubMed] [Google Scholar]
  15. Lopez-Miranda J., Ordovas J. M., Espino A., Marin C., Salas J., Lopez-Segura F., Jimenez-Pereperez J., Perez-Jimenez F. Influence of mutation in human apolipoprotein A-1 gene promoter on plasma LDL cholesterol response to dietary fat. Lancet. 1994 May 21;343(8908):1246–1249. doi: 10.1016/s0140-6736(94)92149-0. [DOI] [PubMed] [Google Scholar]
  16. Ma J., Yee A., Brewer H. B., Jr, Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994 Nov 3;372(6501):92–94. doi: 10.1038/372092a0. [DOI] [PubMed] [Google Scholar]
  17. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245–4249. doi: 10.1073/pnas.82.12.4245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McGeer P. L., Kawamata T., Walker D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992 May 8;579(2):337–341. doi: 10.1016/0006-8993(92)90071-g. [DOI] [PubMed] [Google Scholar]
  19. Möckel B., Zinke H., Flach R., Weiss B., Weiler-Güttler H., Gassen H. G. Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J Neurochem. 1994 Feb;62(2):788–798. doi: 10.1046/j.1471-4159.1994.62020788.x. [DOI] [PubMed] [Google Scholar]
  20. Naiki H., Higuchi K., Shimada A., Takeda T., Nakakuki K. Genetic analysis of murine senile amyloidosis. Lab Invest. 1993 Mar;68(3):332–337. [PubMed] [Google Scholar]
  21. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991 Feb 8;541(1):163–166. doi: 10.1016/0006-8993(91)91092-f. [DOI] [PubMed] [Google Scholar]
  22. Nichols W. C., Gregg R. E., Brewer H. B., Jr, Benson M. D. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics. 1990 Oct;8(2):318–323. doi: 10.1016/0888-7543(90)90288-6. [DOI] [PubMed] [Google Scholar]
  23. Nolte R. T., Atkinson D. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys J. 1992 Nov;63(5):1221–1239. doi: 10.1016/S0006-3495(92)81698-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pan K. M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R. J., Cohen F. E. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10962–10966. doi: 10.1073/pnas.90.23.10962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Prelli F., Castaño E., Glenner G. G., Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem. 1988 Aug;51(2):648–651. doi: 10.1111/j.1471-4159.1988.tb01087.x. [DOI] [PubMed] [Google Scholar]
  26. Roher A. E., Lowenson J. D., Clarke S., Wolkow C., Wang R., Cotter R. J., Reardon I. M., Zürcher-Neely H. A., Heinrikson R. L., Ball M. J. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem. 1993 Feb 15;268(5):3072–3083. [PubMed] [Google Scholar]
  27. Selkoe D. J., Abraham C. R., Podlisny M. B., Duffy L. K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem. 1986 Jun;46(6):1820–1834. doi: 10.1111/j.1471-4159.1986.tb08501.x. [DOI] [PubMed] [Google Scholar]
  28. Soto C., Frangione B. Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neurosci Lett. 1995 Feb 17;186(2-3):115–118. doi: 10.1016/0304-3940(95)11299-c. [DOI] [PubMed] [Google Scholar]
  29. Soutar A. K., Hawkins P. N., Vigushin D. M., Tennent G. A., Booth S. E., Hutton T., Nguyen O., Totty N. F., Feest T. G., Hsuan J. J. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7389–7393. doi: 10.1073/pnas.89.16.7389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D. B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993 Nov;61(5):1965–1968. doi: 10.1111/j.1471-4159.1993.tb09841.x. [DOI] [PubMed] [Google Scholar]
  31. Weisgraber K. H., Roses A. D., Strittmatter W. J. The role of apolipoprotein E in the nervous system. Curr Opin Lipidol. 1994 Apr;5(2):110–116. doi: 10.1097/00041433-199404000-00007. [DOI] [PubMed] [Google Scholar]
  32. Wisniewski T., Castaño E. M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994 Nov;145(5):1030–1035. [PMC free article] [PubMed] [Google Scholar]
  33. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992 Feb 3;135(2):235–238. doi: 10.1016/0304-3940(92)90444-c. [DOI] [PubMed] [Google Scholar]
  34. Wisniewski T., Ghiso J., Frangione B. Alzheimer's disease and soluble A beta. Neurobiol Aging. 1994 Mar-Apr;15(2):143–152. doi: 10.1016/0197-4580(94)90105-8. [DOI] [PubMed] [Google Scholar]
  35. Wisniewski T., Lalowski M., Golabek A., Vogel T., Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet. 1995 Apr 15;345(8955):956–958. doi: 10.1016/s0140-6736(95)90701-7. [DOI] [PubMed] [Google Scholar]
  36. Wisniewski T., Lalowski M., Levy E., Marques M. R., Frangione B. The amino acid sequence of neuritic plaque amyloid from a familial Alzheimer's disease patient. Ann Neurol. 1994 Feb;35(2):245–246. doi: 10.1002/ana.410350223. [DOI] [PubMed] [Google Scholar]
  37. Zlokovic B. V., Martel C. L., Mackic J. B., Matsubara E., Wisniewski T., McComb J. G., Frangione B., Ghiso J. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1431–1437. doi: 10.1006/bbrc.1994.2825. [DOI] [PubMed] [Google Scholar]
  38. von Eckardstein A., Funke H., Walter M., Altland K., Benninghoven A., Assmann G. Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. J Biol Chem. 1990 May 25;265(15):8610–8617. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES